DE153998T1 - Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta-cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten. - Google Patents

Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta-cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten.

Info

Publication number
DE153998T1
DE153998T1 DE198484113923T DE84113923T DE153998T1 DE 153998 T1 DE153998 T1 DE 153998T1 DE 198484113923 T DE198484113923 T DE 198484113923T DE 84113923 T DE84113923 T DE 84113923T DE 153998 T1 DE153998 T1 DE 153998T1
Authority
DE
Germany
Prior art keywords
compounds
cyclodextrins
piroxicam
complex
complexing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE198484113923T
Other languages
English (en)
Inventor
Paolo Chiesi
Vittorino Parma Servadio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of DE153998T1 publication Critical patent/DE153998T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (9)

EP 84113923.1 Chiesi Farmaceutici S.p.A., Parma/Italien Patentansprüche für die benannten Staaten BE, CH, DE, FR, GB, IT, LI, LU, NL, SE (Übersetzung nach Artikel 67 EPÜ)
1. Verbindungen, hergestellt durch Komplexierung von Piroxicam mit Cyclodextrinen des α-, ß- oder γ-Typs in einem Verhältnis von Piroxicam und Cyclodextrinen von 1 : 1 bis 1 : 10.
2. Verbindungen nach Anspruch 1, dadurch gekennzeichnet, daß das Verhältnis von Piroxicam/Cyclodextrin 1 : 2,5 ist.
3. Verbindungen nach Anspruch 1, dadurch gekennzeichnet, daß die Cyclodextrine vom ß-Typ sind.
4. Verfahren zur Herstellung von Verbindungen nach jedem der -Ansprüche 1 bis 3, dadurch gekennzeichnet, daß man Piroxicam und die Cyclodextrine in einer wäßrigen Lösung zur Umsetzung bringt, aus der man den Komplex
durch Kristallisation gewinnt.
5. Verfahren zur Herstellung von Verbindungen nach jedem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß
man eine Lösung von Piroxicam in einem organischen Medium mit einer wäßrigen Lösung von ß-Cyclodextrin
unter Rühren zur Umsetzung bringt und den erhaltenen Komplex anschließend durch Kristallisation abtrennt.
6. Verfahren zur Herstellung vcm Verbindungen nach jedem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß
man die zwei Komponenten unter Rühren in einer heißen wäßrigen Lösung von Ammoniumhydroxid zur Umsetzung
bringt.
1
7. Verfahren nach Anspruch 6, dadurch gekennzeichnet, daß man den Komplex durch Eindampfen des Lösungsmittels und anschließendes Trocknen isoliert.
5
8. Verfahren nach Anspruch 6, dadurch gekennzeichnet, daß man den Komplex durch Gefriertrocknung der Lösung gewinnt.
9. Verfahren nach Anspruch 6, dadurch gekennzeichnet, daß 10 man den Komplex durch Zerstäubung der Lösung in einem Luftstrom gewinnt.
20
25
30
35
DE198484113923T 1984-02-22 1984-11-17 Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta-cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten. Pending DE153998T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT19735/84A IT1196033B (it) 1984-02-22 1984-02-22 Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche

Publications (1)

Publication Number Publication Date
DE153998T1 true DE153998T1 (de) 1986-04-10

Family

ID=11160778

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8484113923T Expired - Lifetime DE3482041D1 (de) 1984-02-22 1984-11-17 Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta-cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten.
DE198484113923T Pending DE153998T1 (de) 1984-02-22 1984-11-17 Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta-cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE8484113923T Expired - Lifetime DE3482041D1 (de) 1984-02-22 1984-11-17 Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta-cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten.

Country Status (19)

Country Link
US (1) US4603123A (de)
EP (1) EP0153998B1 (de)
JP (1) JPS60208979A (de)
KR (1) KR870001960B1 (de)
AT (1) ATE52263T1 (de)
AU (1) AU550007B2 (de)
BE (1) BE900836A (de)
CA (1) CA1234106A (de)
DE (2) DE3482041D1 (de)
DK (1) DK164911C (de)
ES (1) ES8504789A1 (de)
IE (1) IE58231B1 (de)
IT (1) IT1196033B (de)
MY (1) MY101374A (de)
NZ (1) NZ211114A (de)
PH (1) PH22075A (de)
PT (1) PT79997B (de)
SG (1) SG53690G (de)
ZA (1) ZA848156B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
IT1204725B (it) * 1987-06-17 1989-03-10 Edmond Pharma Srl Complessi di inclusione del dipiridamolo con ciclodestrine
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
DE3809808A1 (de) * 1988-03-23 1989-10-05 Hexal Pharma Gmbh & Co Kg Feste, insbesondere festorale und rektale, etofenamat enthaltende arzneimittel
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
IT1241088B (it) * 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US6667056B2 (en) * 1997-07-23 2003-12-23 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
FR2786395A1 (fr) * 1998-12-01 2000-06-02 Virbac Sa Compositions seches solubles en presence d'eau et evitant la reaction de maillard a l'etat sec, leur preparation et leurs applications
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US20020160991A1 (en) * 2000-12-04 2002-10-31 Liming Shao Orally-bioavailable formulations of fentanyl and congeners thereof
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
ATE359827T1 (de) * 2002-06-17 2007-05-15 Chiesi Farma Spa Prozess für die vorbereitung von piroxicam: beta- cyclodextrin einschlusskomplexe
EP1582221A1 (de) * 2004-03-31 2005-10-05 Chiesi S.A. Orale Pharmazeutische zusammensetzung zur Geschmacksmaskierung
ATE504316T1 (de) 2004-04-01 2011-04-15 Pf Medicament Einschlusskomplexe enthaltend piroxicam, ein cyklodextrin und arginin
PT1586310E (pt) * 2004-04-15 2007-02-28 Helm Ag Processo para a preparação de adsorvatos de valsartan na forma de pó solto
US20060024922A1 (en) * 2004-07-27 2006-02-02 Da-Tung Wen Method for cutting wafer
WO2006013039A2 (en) * 2004-08-02 2006-02-09 Chiesi Farmaceutici S.P.A. A process for the preparation of a piroxicam: beta­cyclodextrin inclusion compound
FR2876910B1 (fr) 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
CL2007003876A1 (es) * 2007-12-28 2008-03-07 Univ De Concepcion Y Lab Andro Complejo de inclusion que esta formado por disulfiram y ciclodextrina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de la dependencia de alcohol y cocaina.
KR101383941B1 (ko) * 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827452A (en) * 1955-05-31 1958-03-18 Univ Minnesota Stabilization of materials
US3969338A (en) * 1971-03-15 1976-07-13 Institut National De La Recherche Agronomique Protein obtained from cakes of vegetable origin
HU184066B (en) * 1979-12-28 1984-06-28 Chinoin Gyogyszer Es Vegyeszet Plant growth regulating substance and process for preparing such compound
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤

Also Published As

Publication number Publication date
EP0153998B1 (de) 1990-04-25
EP0153998A3 (en) 1987-01-14
AU3892385A (en) 1985-08-29
KR850006133A (ko) 1985-10-02
EP0153998A2 (de) 1985-09-11
US4603123A (en) 1986-07-29
DK76085D0 (da) 1985-02-19
PT79997A (en) 1985-03-01
MY101374A (en) 1991-10-23
IE58231B1 (en) 1993-08-11
JPH0370705B2 (de) 1991-11-08
DE3482041D1 (de) 1990-05-31
DK164911B (da) 1992-09-07
BE900836A (fr) 1985-02-15
DK164911C (da) 1993-01-18
KR870001960B1 (ko) 1987-10-23
IE850325L (en) 1985-08-22
IT8419735A0 (it) 1984-02-22
JPS60208979A (ja) 1985-10-21
AU550007B2 (en) 1986-02-27
DK76085A (da) 1985-08-23
PT79997B (en) 1987-01-13
CA1234106A (en) 1988-03-15
ZA848156B (en) 1985-06-26
PH22075A (en) 1988-05-20
NZ211114A (en) 1987-09-30
ES536909A0 (es) 1985-05-01
IT1196033B (it) 1988-11-10
ES8504789A1 (es) 1985-05-01
SG53690G (en) 1990-11-23
ATE52263T1 (de) 1990-05-15

Similar Documents

Publication Publication Date Title
DE153998T1 (de) Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta-cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten.
KR880012713A (ko) 진주광택 안료제제
KR920004555A (ko) 다중불포화된 장쇄 지방산 및 이들의 유도체의 시클로덱스트린과의 복합체의 제조방법 및 이로부터 만들어진 복합체
ATE247486T1 (de) Pharmazeutische zusammensetzungen, enthaltend diclofenac und 2-hydroxypropyl-beta-cyclodextrin
CH649091A5 (de) Einschlusskomplexe von cyclodextrinen und starken anorganischen oxysaeuren und ihre herstellung.
DE2948869C2 (de)
DE2421655A1 (de) Thermoplastische werkstoffe ohne thrombose erzeugende wirkung
DE1963081C3 (de) Verfahren zur Herstellung von Gelatinekapseln
DE268885T1 (de) Verfahren zur kontrollierten depolymerisierung von polysacchariden.
KR930004330A (ko) β-시클로덱스트린 유도체의 폴리술페이트 및 그의 제조방법
NL183726C (nl) Werkwijze voor het bereiden van een hardbare bekledingssamenstelling.
EP0283573B1 (de) Wasserfreie Applikationsform niedermolekularer Alkalihuminate
EP0017235A1 (de) Verfahren zur omega-123J-Markierung von Fettsäuren
CH645918A5 (de) Oxydations-reduktions-reagens fuer den einsatz in nass-desulfurierungsprozessen.
DE659120C (de) Mittel zur Herstellung von Dauerwellen
DE69600185T2 (de) Gebrauchsfertige Augentropfen enthaltend Indomethacin
WO1996040262A3 (en) Process for preparing encapsulated water soluble beta-carotene
DE2320678A1 (de) Stickstoffduenger
DE1768362A1 (de) Dextranderivat und Verfahren zu seiner Herstellung
DE898813C (de) Verfahren zur Herstellung von stickstoffhaltigen Aldehydharzprodukten
DE2215160A1 (de) Verfahren zur Herstellung eines wasserunlöslichen, enzymatisch aktiven Erzeugnisses
DE158879T1 (de) Verbindungen mit cardiotropischer aktivitaet, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen.
DE1099130B (de) Verfahren zur Herstellung eines Mittels zum Blondieren oder Faerben des Haares
EP0498333A2 (de) Verfahren zur Herstellung einer mit Technetium-99m markierten organspezifischen Substanz
DE531846C (de) Verfahren zur Herstellung von physiologisch wirksamen Kupfer-Arsenverbindungen